• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Open Forum Infect Dis . Clinical and Virologic Characteristics and Outcomes of Coronavirus Disease 2019 at a Cancer Center

tetano

Editor, Senior Moderator
Open Forum Infect Dis


. 2021 Apr 16;8(6):ofab193.
doi: 10.1093/ofid/ofab193. eCollection 2021 Jun.
Clinical and Virologic Characteristics and Outcomes of Coronavirus Disease 2019 at a Cancer Center


Leah H Yoke[SUP] 1 2 [/SUP], Juhye M Lee[SUP] 1 [/SUP], Elizabeth M Krantz[SUP] 1 [/SUP], Jessica Morris[SUP] 1 [/SUP], Sara Marquis[SUP] 1 [/SUP], Pooja Bhattacharyya[SUP] 1 2 [/SUP], Lisa So[SUP] 1 2 [/SUP], Francis X Riedo[SUP] 3 [/SUP], Jason Simmons[SUP] 2 4 [/SUP], Ali Raza Khaki[SUP] 5 6 7 [/SUP], Guang-Shing Cheng[SUP] 5 8 [/SUP], Alexander L Greninger[SUP] 1 9 [/SUP], Steven A Pergam[SUP] 1 2 [/SUP], Alpana Waghmare[SUP] 1 10 11 [/SUP], Chikara Ogimi[SUP] 1 10 11 [/SUP], Catherine Liu[SUP] 1 2 [/SUP]



Affiliations

Abstract

Background: High morbidity and mortality have been observed in patients with cancer and coronavirus disease 2019 (COVID-19); however, there are limited data on antimicrobial use, coinfections, and viral shedding.
Methods: We conducted a retrospective cohort study of adult patients at the Seattle Cancer Care Alliance diagnosed with COVID-19 between February 28, 2020 and June 15, 2020 to characterize antimicrobial use, coinfections, viral shedding, and outcomes within 30 days after diagnosis. Cycle threshold values were used as a proxy for viral load. We determined viral clearance, defined as 2 consecutive negative results using severe acute respiratory syndrome coronavirus 2 reverse-transcription polymerase chain reaction results through July 30, 2020.
Results: Seventy-one patients were included with a median age of 61 years; 59% had a solid tumor. Only 3 patients had documented respiratory bacterial coinfection. Empiric antibiotics for pneumonia were prescribed more frequently early in the study period (February 29-March 28, 2020; 12/34) compared to the later period (March 29-June 15, 2020; 2/36) (P = .002). The median number of days from symptom onset to viral clearance was 37 days with viral load rapidly declining in the first 7-10 days after symptom onset. Within 30 days of diagnosis, 29 (41%) patients were hospitalized and 12 (17%) died. Each additional comorbidity was associated with 45% lower odds of days alive and out of hospital in the month following diagnosis in adjusted models.
Conclusions: Patients at a cancer center, particularly those with multiple comorbidities, are at increased risk of poor outcomes from COVID-19. Prolonged viral shedding is frequently observed among cancer patients, and its implications on transmission and treatment strategies warrant further study.

Keywords: COVID-19; antimicrobial use; cancer; clinical outcomes; viral shedding.
 
Back
Top Bottom